Glioblastoma multiforme is the most common aggressive adult primary tumour of the central nervous system. Treatment includes surgery, radiotherapy and adjuvant temozolomide (TMZ) chemotherapy. TMZ is an alkylating agent prodrug, delivering a methyl group to purine bases of DNA (O6-guanine; N7-guanin …

Temozolomide is an alkylating agent used to treat serious brain cancers; most commonly as second-line treatments for astrocytoma and as the first-line treatment for glioblastoma. [4][6][7] Olaparib in combination with temozolomide demonstrated substantial clinical activity in relapsed small cell lung cancer. [8] .

Primarily defined histopathologically by necrosis and microvascular proliferation (WHO grade IV classification), glioblastomas are commonly treated through radiotherapy and concomitant alkylation-based chemotherapy with temozolomide. 9 Temozolomide (TMZ) is a small (194 Da) lipophilic alkylating agent of the imidazotetrazine class that is ...

TMZ has a low molecular weight of 194.154 g/mol, a lipophilic character, and acts as a potent alkylating agent. Currently, TMZ represents the standard adjuvant treatment in newly diagnosed GBM patients, along with surgery and radiation therapy .

Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.

The primary endogenous DNA repair mechanisms that counteract the DNA damage caused by TMZ, and are thus commonly implicated in TMZ resistance, include MGMT, BER and MMR. TMZ: temozolomide; MTIC: metabolite 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide; MGMT: O6-methylguanine-DNA methyltransferase; BER: base excision repair; MMR: mismatch repair

2008年6月10日 · Our aim is to present new developments in understanding glioma resistance to alkylating agents and synergy between different treatment modalities (i.e. radiotherapy and TMZ), and emphasize new...

Temozolomide (TMZ), an oral alkylating prodrug which delivers a methyl group to purine bases of DNA (O6-guanine; N7-guanine and N3-adenine), is frequently used together with radiotherapy as part of the first-line treatment of high-grade gliomas.

2015年8月26日 · The results of brain tumours treatment with TMZ suggest the new mechanism of modulation epigenetic marker in cancer cells. A high TMZ concentration induced a significant increase of m5C content in DNA in the short time, but a low TMZ concentration at longer time hypomethylation is observed for whole range of TMZ concentrations.

2021年3月8日 · Schema of mechanism with involvement of ROS-related factors to take place in mitochondria in temozolomide (TMZ) resistance. Toxicity of TMZ induces excessive superoxide generation which requires activation of ROS scavengers to detoxify. Accumulation of ROS, on the other hand, promotes tumorigenesis.